Managing the financial impact of cancer treatment: The role of clinical practice guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 8, 2012, Pages 1037-1042

  Ramsey, Scott ^a,b,c   Shankaran, Veena ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c International Society of Pharmacoeconomics and Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; PRACTICE GUIDELINE; REVIEW; STOMACH CANCER; UNITED STATES;

EID: 84865322757     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0106     Document Type: Review

References (24)

1. Kaiser Family Foundation. Employer Health Benefits 2008 Annual Survey. Available at http://ehbs.kff.org/pdf/7790.pdf.
2. Shankaran V, Jolly S, Blough D, Ramsey SD. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol 2012;30:1608-1614.
3. Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 2011;20:2006-2014.
4. Brody H. Medicine's ethical responsibility for health care reform - the Top Five list. N Engl J Med 2010;362:283-285.
5. Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key oppotunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012;30:1715-1724.
6. Burstein HJ. If all treatments cost the same, why not choose the least expensve option? JNCCN 2012;10:425-426.
7. National Comprehensive Cancer Network. National Comprehensive Cancer Network Drugs & Biologics Compendium (NCCN Compendium). Available at: http://www.nccn.org/professionals/drug-compendium/content/contents.asp.
8. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009;27:3868-874.
9. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-2019.
10. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-4705.
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
12. Centers for Medicare & Medicaid Services. 2012 ASP Drug Pricing Files. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part- B-Drugs/McrPartBDrugAvgSalesPrice/2012ASPFiles.html.
13. Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 2007;7:91.
14. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-2019.
15. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006-2012.
16. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-4106.
17. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008;26:689-690.
18. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779-4786.
19. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
20. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-1676.
21. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997.
22. Cunningham D, Okines AF, Ashley S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
23. Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2011;125:191-200.
24. Kelley RK, Venook AP. Nonadherence to imatinib during an economic downturn. N Engl J Med 2010;363:596-598.